Bali Medical Journal (Bali MedJ) 2024, Volume 13, Number 1: 270-277
Interleukin-17 expression is associated with survival in pediatric osteosarcoma
Muhammad Riza1,2*, Harsono Salimo1,2, Brian Wasita1,3, Vitri Widyaningsih1,4, Bambang Purwanto1,5, Pamudji Utomo1,6, Soestrisno1,7, Fikar Arsyad Hakim3, Fairuz Zahidah2, Janur Wayanshakty2
1Doctoral Program of Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia;2Pediatrics Department Faculty of Medicine Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia;3Department of Anatomical Pathology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia;4Department of Public Health, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia, Indonesia;5Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta. Indonesia; 6Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Sebelas Maret, Prof. Dr. R. Soeharso Orthopedics Hospital, Surakarta, Indonesia;7Department of Obstetrics and Gynecology, Dr. Moewardi Hospital, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia
ABSTRACT
Background : Osteosarcoma is a cancerous tumor that develops from bone-forming mesenchymal cells. The cause of osteosarcoma appears to be multifaceted, and cytokine production is a potential causative factor. T helper 17 cells are responsible for producing the cytokine interleukin 17 (IL-17), and its association with cancer progression remains a subject of ongoing debate. This study aimed to analyze IL-17 expression before and after neoadjuvant chemotherapy and the relationships between prognostic factors and survival.
Methods : We investigated the expression of IL-17 in osteosarcoma tissues from 22 pediatric patients who underwent neoadjuvant chemotherapy. Histopathological and immunohistochemical methods were used to assess IL-17 expression prior to the patients undergoing neoadjuvant chemotherapy. IL-17 expression before chemotherapy was classified as low or high based on the median data. Survival was calculated using the Kaplan–Meier survival analysis with the log-rank test.
Result : The following characteristics were found to be associated with longer survival: male, age > 10 years old, distal location of tumor, low-grade tumor, and tumor with no metastasis; however, there were no statistically significant differences (p > 0.05). Binary logistic analysis showed that high expression of IL-17 based on the median data before neoadjuvant chemotherapy (>1.62%) were significantly associated with reduced survival (p = 0.010). The mean estimated overall duration of survival was 19.4 months (95% confidence interval (CI): 14.5-24.3) for low IL-17 expression and 14.0 months (95%CI: 8.3–19.7) for high IL-17 expression based on the median data. There was no statistically significant difference in the overall survival (p > 0.05).
Conclusion : High expression of IL-17 before neoadjuvant chemotherapy after neoadjuvant chemotherapy were associated with poor survival among pediatric osteosarcoma patients. These findings suggest that IL-17 is a potential prognostic biomarker for pediatric osteosarcoma.
Keywords: IL-17, Pediatric, Osteosarcoma, Survival.
*Corresponding to: Muhammad Riza; 1Doctoral Program of Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia;2Pediatrics Department Faculty of Medicine Universitas Sebelas Maret/Dr. Moewardi General Hospital, Surakarta, Indonesia;m_riza@staff.uns.ac.id
Cite This Article: Riza, M., Salimo, H., Wasita, B., Widyaningsih, V., Purwanto, B., Utomom, P., Soetrisno., Hakim, F.A., Zahidah, F., Wayanshakty, J. 2024. Interleukin-17 expression is associated with survival in pediatric osteosarcoma.Bali Medical Journal13(1): 270-277. DOI: 10.15562/bmj.v13i1.4949